Sentinel Lymph Node Biopsy Alone after Neoadjuvant Chemotherapy in Patients with Initial Cytology-Proven Axillary Node Metastasis

Ji Young Kim*, Min Kuk Kim, Jeong Eon Lee**, Yongsik Jung, Soo Youn Bae, Se Kyung Lee, Won Ho Kil, Seok Won Kim, Ku Sang Kim, Seok Jin Nam, Sehwan Han

Department of Surgery, Ajou University School of Medicine, Suwon; MD Hospital, Seoul; Department of Surgery, Sungkyunkwan University School of Medicine, Seoul; Ulsan City Hospital, Ulsan, Korea

**These authors equally contributed to this work.

**E-mail: smartblade@gmail.com
Tel: +82-31-219-5200, Fax: +82-31-219-5755
Ro, Yeongtong-gu, Suwon 443-721, Korea

INTRODUCTION

Accurate staging and proper management of axillary lymph nodes (ALNs) are important for the treatment of breast cancer. Nodal staging is successfully achieved by sentinel lymph node biopsy (SLNB) in clinically node-negative patients [1]. Neoadjuvant chemotherapy (NAC), was initially used to convert inoperable locally advanced breast cancer to operable status, and has been recently used to downsize tumors to allow for breast conservation surgery [2,3]. Moreover, NAC has been shown to effectively downstage the ALNs [4-6]. However, a complete ALN dissection (ALND), regardless of the NAC response, remains the standard management for all patients with a cytology-proven ALN metastasis at diagnosis [7].

NAC offers the advantages of real-time monitoring and confirmation of the treatment effects in terms of the pathological complete response (pCR) [8,9]. Several trials have shown that the achievement of a pCR after chemotherapy strongly correlates with favorable long-term outcomes among the different breast cancer subtypes [10,11]. Of note, the triple-negative and human epidermal growth factor receptor 2 (HER2) subtypes are more likely to obtain pCR when NAC is administered, as compared to the luminal A subtype [12,13].

The rate of conversion to negative ALN after NAC ranges from 30% to 40%. These patients would not be expected to benefit from ALND and may experience complications from the procedure. ALN pCR is associated with an excellent prognosis despite an excess of aggressive features [14,15]. Furthermore, growing evidence suggests that the nodal stage after NAC reflects the prognosis more accurately than the initial axillary status [16]. As a result, questions are arising whether removal of the lymph nodes with ALND is indeed needed for...
such patients.

The objectives of this study were to evaluate the feasibility and accuracy of SLNB, to assess the patient selection factors associated with SLNB alone and to determine whether SLNB alone versus SLNB with ALND is associated with differences in the axillary recurrence or in the survival of breast cancer patients with initial cytology-proven axillary node metastasis after NAC.

METHODS

This was a retrospective two-center study conducted at the Samsung Medical Center and the Ajou Medical Center. Data of patients with a diagnosis of invasive breast cancer and axillary node-positive disease identified by ultrasound-guided fine-needle aspiration (FNA) and treated with NAC followed by definitive surgery between January 2007 and August 2013 were collected and reviewed. Clinical and pathologic characteristics were analyzed at diagnosis, after chemotherapy and after surgery. Patients with bilateral breast cancer, previous ipsilateral axillary surgery, inflammatory breast cancer or distant metastasis were excluded. The NAC regimens were decided at the discretion of the treating oncologists. Ultrasound of the regional lymph nodes and breast magnetic resonance imaging (MRI) were performed before and after NAC. The nodal size, morphology, and clinical response were assessed by ultrasound and MRI. Both, radioactive colloid and blue dye were used for sentinel lymph node (SLN) detection. Non-blue or non-hot nodes with suspicious features for metastases, and enlarged or hard nodes on palpation, were also harvested. Blue or hot nodes as well as suspicious lymph nodes, were defined as sentinel nodes. Preoperative lymphatic mapping and SLNB were performed along with, or without, completion ALND. Most patients subsequently received completion ALND after SLNB, regardless of the axillary clinical response after chemotherapy, following general recommendations at the time of surgery. In cases where the patients had converted to clinically negative axillary status after chemotherapy and had confirmed negative SLN status on pathology, further ALND was omitted when the physician and patient made a decision before surgery to avoid possible morbidities from ALND.

This study was approved by the Institutional Review Boards of the Samsung Medical Center and Ajou Medical Center (approval numbers: SMC 2013-10-128 and AMC 2013-13-474).

Patient grouping

A total of 386 patients with a diagnosis of invasive breast cancer and metastatic axillary nodes documented by ultrasound-guided FNA treated with NAC followed by surgery were identified. Of these, 266 patients (68.9%) underwent complete ALND regardless of the axillary clinical response assessment after chemotherapy, following general recommendations. SLNB was attempted for axillary staging at the time of surgical treatment in 120 patients (31.1%) with a complete or near complete clinical response on axillary ultrasound and MRI after NAC. We classified the patients into five categories: group 1, patients for whom SLNB revealed no residual axillary metastasis and no further dissection was performed; group 2, patients with negative SLN status undergoing further ALND; group 3, patients with positive or undetected SLNs undergoing further ALND; group 4, patients without residual axillary metastasis on pathology undergoing complete ALND regardless of the clinical response; and group 5, patients with pathologic nodal positive disease undergoing ALND (Figure 1). We analyzed and compared the outcomes, including the prognoses and survivals, between all groups.

During the patient grouping, we had some difficulties owing to the inherent biases of a retrospective design in distinguishing between groups 1 and 2, because some of the patients had conglomerated SLNs after chemotherapy or there were, a small number of retrieved lymph nodes even after axillary dissection. Thus, we created the following criteria for dividing the groups: the number of retrieved sentinel nodes was limited to seven for distinguishing SLNB from ALND, and the surgeon’s intention of SLNB or axillary dissection was considered in addition to the number of dissected axillary nodes.

Statistical analysis

The chi-square test and Spearman correlation coefficient were used to compare discrete variables. Survival analysis was
performed using the Kaplan-Meir method and the $p$-value was calculated by using the log-rank test. A $p < 0.05$ indicated statistical significance. SPSS version 18.0 (SPSS Inc., Chicago, USA) was used for all statistical analyses.

RESULTS

Patient and tumor characteristics

The patient and tumor characteristics are summarized according to the different groups in Table 1. When we compared the patient demographics and other variables, including breast pathology after surgery, the patients in the sentinel node negative groups had significantly higher rates of ypT0 or ypTis. Furthermore, there were more patients with hormone receptor negative tumors in groups 1 and 2 than in the sentinel node negative groups.

Diagnostic performance of SLNB

The diagnostic performances of SLNB after NAC in node-positive breast cancer are demonstrated in Table 2. SLN identification was successful in 115 patients (95.8%). The median number of retrieved SLNs was 3.0 (range, 1–7). The rate of no residual axillary metastases and false-negative ratio were calculated with data of 89 patients (groups 2 and 3). The SLNB after NAC accurately predicted the nodal positivity in 18 of 20 patients (90.0%), yielding a false-negative rate of 10.0%. The diagnostic performances according to the number of SLNs examined in all patients who underwent SLNB and further ALND are demonstrated in Table 3. Although SLNB with less

Table 1. Characteristics of sentinel lymph node biopsy group and pathological node negative axillary lymph node dissection group

| Variable                        | Total (n=199) No. (%) | Group 1 (n=31) No. (%) | Group 2 (n=20) No. (%) | Group 3 (n=69) No. (%) | Group 4 (n=79) No. (%) | $p$-value |
|---------------------------------|-----------------------|------------------------|------------------------|------------------------|------------------------|-----------|
| Age at diagnosis (yr)*          | 45.6±9.3              | 47.6±8.1               | 46.3±10.8              | 43.3±9.2               | 47.2±10.3              | 0.681     |
| Menopausal                      |                       |                        |                        |                        |                        | 0.279     |
| Premenopausal                   | 129 (64.8)            | 20 (64.5)              | 14 (70.0)              | 50 (72.5)              | 45 (57.0)              |           |
| Postmenopausal                  | 70 (35.2)             | 11 (35.5)              | 6 (30.0)               | 19 (27.5)              | 34 (43.0)              |           |
| Histologic type                 |                       |                        |                        |                        |                        | 0.598     |
| Ductal                          | 195 (98.0)            | 31 (100.0)             | 20 (100.0)             | 68 (98.6)              | 76 (96.2)              |           |
| Lobular or others               | 4 (2.0)               | 0                      | 0                      | 1 (1.4)                | 3 (3.8)                |           |
| Hormone receptor status         |                       |                        |                        |                        |                        | <0.001    |
| Positive                        | 96 (48.2)             | 11 (35.5)              | 8 (40.0)               | 42 (60.9)              | 35 (44.3)              |           |
| Negative                        | 103 (51.7)            | 20 (64.5)              | 12 (60.0)              | 27 (39.1)              | 44 (55.7)              |           |
| HER2 status                     |                       |                        |                        |                        |                        | 0.007     |
| Positive                        | 75 (37.7)             | 14 (45.2)              | 11 (55.0)              | 15 (21.7)              | 35 (44.3)              |           |
| Negative                        | 124 (62.3)            | 17 (54.8)              | 9 (45.0)               | 54 (78.3)              | 44 (55.7)              |           |
| Type of surgery                 |                       |                        |                        |                        |                        | 0.309     |
| Conserving                      | 147 (73.8)            | 28 (90.3)              | 15 (75.0)              | 51 (73.9)              | 53 (67.1)              |           |
| Mastectomy                      | 52 (26.1)             | 3 (9.7)                | 5 (25.0)               | 18 (26.1)              | 26 (32.9)              |           |
| Pathologic tumor stage          |                       |                        |                        |                        |                        | <0.001    |
| ypT0-is                         | 84 (42.2)             | 21 (67.7)              | 13 (65.0)              | 11 (15.9)              | 39 (49.4)              |           |
| ypT1-2                          | 96 (48.2)             | 10 (32.3)              | 7 (35.0)               | 46 (66.7)              | 33 (41.8)              |           |
| ypT3                            | 19 (9.5)              | 0                      | 0                      | 12 (17.4)              | 7 (8.9)                |           |
| Histologic grade                |                       |                        |                        |                        |                        | <0.001    |
| I/II                            | 94 (47.2)             | 7 (22.6)               | 5 (25.0)               | 54 (78.3)              | 28 (35.4)              |           |
| III                             | 107 (53.8)            | 15 (48.4)              | 8 (40.0)               | 38 (55.1)              | 46 (66.2)              |           |
| Lymphovascular invasion         |                       |                        |                        |                        |                        | <0.001    |
| Absent                          | 45 (22.6)             | 4 (12.9)               | 3 (15.0)               | 27 (39.1)              | 11 (13.9)              |           |
| Present                         |                       |                        |                        |                        |                        |           |

Table 2. Diagnostic performance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial cytology-proven nodal disease at presentation

| Findings of SLN                                    | No. (%) |
|--------------------------------------------------|---------|
| SLN identification rate after NAC                | 115/120 (95.8) |
| No. of nodes retrieved*                          | 3 (1–7) |
| No residual axillary metastases (ypN0)           | 18/89 (20.2) |
| Residual axillary metastases                     | 71/89 (79.8) |
| Residual metastases limited to SLNs              | 27/70 (38.6) |
| Falsely negative SLNs                            | 2/20 (10.0) |

SLN= sentinel lymph node; NAC= neoadjuvant chemotherapy.
*Median (range).
than three retrieved SLNs was performed in more than half of the patients (60.0%), there were no false negative SLNB findings in those patients.

Survivals

The median follow-up time was 19.5 months (range, 2–65 months). There was no difference in the overall survival among groups 1, 2, and 4 (Figure 2A), and no patient expired in all groups except for in group 5. The comparison of disease-free survival in groups 1 and 2 showed no statistical significant difference (p = 0.314). On the other hand, there was a significant difference in the disease-free survival rate between groups 1 and 4 (77.1% vs. 85.4%). The patients treated with complete ALND and showing a pathologic complete node response had a significantly better disease-free survival compared to group 1 (p = 0.031) (Figure 2B).

During the study period, five of the 31 patients (16.1%) in the group 1 experienced two systemic and three regional recurrences. Table 4 summarizes the types of recurrences and clinical characteristics in this group. Further, in the SLNB

| No. of retrieved SLNs | No. of cases (n = 89) | Status of SLNB, No. (%) |
|----------------------|-----------------------|------------------------|
|                     | True positive | True negative | False negative |
| 1                    | 12 (63.2)     | 7 (100.0)      | 0             |
| 2                    | 11 (68.8)     | 5 (100.0)      | 0             |
| 3                    | 19 (90.5)     | 1 (50.0)       | 1 (50.0)      |
| ≥ 4                  | 22 (78.6)     | 5 (83.3)       | 1 (16.6)      |
| Not found            | -             | -              | -             |

SLN = sentinel lymph node; SLNB = sentinel lymph node biopsy.

Table 4. Type of recurrence in patients with sentinel lymph node biopsy only group after neoadjuvant chemotherapy in cytology-proven node positive disease

| Case | Recurrence | DFS time (mo) | HR status | HER2 status | Breast pCR | No. of retrieved SLNs |
|------|------------|---------------|-----------|-------------|------------|-----------------------|
| 1    | Brain      | 5             | Negative  | Positive    | Yes        | 3                     |
| 2    | Brain      | 6             | Positive  | Positive    | No         | 3                     |
| 3    | SCN        | 6             | Positive  | Negative    | Yes        | 4                     |
| 4    | SCN        | 7             | Negative  | Negative    | No         | 5                     |
| 5    | Axillary   | 10            | Negative  | Negative    | No         | 2                     |

DFS = disease-free survival; HR = hormone receptor; HER2 = human epidermal growth factor receptor 2; pCR = pathological complete remission; SLN = sentinel lymph node; SCN = supraclavicular node.

Figure 2. Kaplan-Meier survival curves for overall survival and disease-free survival in all groups. The p-value was calculated using log-rank test. The comparison of overall survival (A) in groups 1, 2, 3, 4, and 5 showed no statistical significant difference. There was a significant difference in the disease-free survival rate (B) between groups 1 and 4 (77.1% vs. 85.4%, p = 0.031).

Figure 3. Kaplan-Meier survival curves for axillary event-free survival in groups 1, 2, and 4 (3.3%, 5.0%, and 1.3%, log-rank test, p > 0.05).
alone group, two patients with HER2-positive tumors developed neurologic symptoms and were diagnosed with brain metastases within 6 months after surgery. Of the patients with recurrences in the SLNB alone group, axillary recurrence occurred in only one patient at 10 months postoperatively. The rate of axillary recurrence demonstrated no statistical differences among the groups (3.3%, 5.0%, and 1.3% for groups 1, 2, and 4, respectively, \( p > 0.05 \)). The rate of axillary recurrence was not significantly worse in the SLNB alone group in the axillary event-free survival analysis as shown in Figure 3.

In the subgroup analysis of disease-free survivals according to hormone receptor status, the survival curve of group 1 was early censored and could not be compared statistically in the hormone-positive subgroup. In hormone receptor-negative patients, there was no statistical difference of recurrence between group 1 versus 2, and group 1 versus 4 (\( p = 0.354 \) and \( p = 0.401 \)) (Figure 4). In the multivariate analysis, no significant independent factors for recurrence were identified in the hormone receptor-negative subgroups.

**DISCUSSION**

During the last few years, there have been a number of clinical trials on the effectiveness and role of SLNB after NAC. According to their findings, SLNB after NAC seems to be an acceptable procedure, despite of varying degrees of false negative results. However, the reliability of SLNB following NAC for patients with initial nodal disease has been questioned, as the only available data have been from small series, reporting false-negative ratios ranging from 7% to 25%. Currently, ALND after NAC in patients with FNA-proven node-positive disease at presentation is recommended. However, the ALN metastases may have been eradicated by the chemotherapy in certain patients, who could consequently be spared ALND. Even in patients with nodal disease at presentation, sparing those patients the morbidity associated with axillary dissection would be desirable. Thus, we expect that the SLNB procedure could represent a restaging tool and aid in the proper management of the axilla in breast cancer patients with ALN metastasis before NAC.

Several reasons for avoiding SLNB after NAC have been suggested. Anatomical alterations of the lymphatic drainage may occur by disruption of the lymphatic vessels by the tumor, inflammation, or fibrosis, or due to blockage by necrotic and/or apoptotic cells. In addition, NAC can induce a nonuniform tumor regression in the axillary nodes [17-19]. However, these allegations of treatment-related alterations in lymphatic drainage have not yet been confirmed [20]. The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-27 trial is one of the largest studies published to date on SLNB after NAC [21]. A total of 428 patients underwent SLNB with concomitant ALND after NAC with an identification rate of 84.8% and a false-negative rate (FNR) of 10.7%. In addition, a meta-analysis of 21 studies, involving a total of 1,273 patients who received NAC followed by SLNB and ALND indicated an average identification rate of 91% and an FNR of 12% [22]. The ACOSOG Z1071 trial showed that the FNR of SLNB after NAC in patients with cN1 breast cancer and at least two SLNs identified at the time of surgery was with 12.6% higher than the expected threshold of 10% [23]. Herein, although all
cases were cytologically proven positive ALNs at presentation, our study showed good results with an FNR of SLNB after NAC of 10.0% and an identification rate of 95.8%. These favorable findings may be the result of the dual-agent mapping technique used. The mean number of retrieved SLNs, including non-SLNs suspicious for metastasis, was 3. Therefore, technical factors are important to minimize the risk of incorrect nodal staging.

Straver et al. [24] analyzed responses to NAC in the axilla of patients with metastatic ALNs proven by cytology at presentation. They reported that a pCR of ALNs was more frequently found in patients with triple-negative tumors and HER2 positive tumors with a pCR of the primary tumor. Similarly, we also found that the luminal subtypes did not show significant differences in the pCR rates between the groups (p > 0.05).

Many studies on SLNB in a neoadjuvant setting used the FNR and identification rate as the endpoints. However, this may not be the best choice. Instead, looking at the regional recurrences when ALND is withheld may be the best endpoint to establish the safety and appropriateness of SLNB. The NSABP B-04 randomized trial of clinically node-negative patients found no significant differences in the survivals among three treatment arms, namely patients who underwent ALND, axillary radiation therapy, or no direct axillary treatment [25]. Bilmoria et al. [26] studied the differences in axillary recurrences and overall survival in pathologically node-positive breast cancer patients who underwent SLNB with or without ALND, and found that all had clinically node-negative disease posttreatment. There were no significant differences in the axillary recurrence and survival for SLNB alone versus ALND after a median follow-up of 63 months.

On the other hand, no long-term outcome data have yet been reported in patients with SLNB only after NAC with cytology proven node-positive disease before NAC. Despite of the relatively short follow-up period, our study found that there was no significant difference in axillary recurrence between the SLNB only and ALND groups.

There are a few limitations of our study that need to be addressed. First, no selection criteria were established, owing to the retrospective study design. However, the majority of patients classified as clinically node-negative after NAC were assigned to the SLNB group. Second, the relatively short follow-up period means that the subtype analyses cannot be considered definitive. Therefore, further follow-up is warranted. Lastly, only a small number of patients could be investigated, owing to the fact that ALND was the standard treatment in previous node-positive breast cancers.

In conclusion, SLNB performed after NAC in patients with initial node-positive breast cancer may help identify downstaging to negative nodal status and reduce the surgical morbidity of these patients by avoiding the need for standard ALND. Future studies with a large number of patients are needed in order to establish the safety of SLNB in conversion to clinically node-negative patients after NAC.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

REFERENCES

1. Veronesi U, Paganelli G, Vale G, Luini A, Zarrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-53.
2. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J Clin Oncol 2004;22: 2303-12.
3. Loibl S, von Minckwitz G, Raab G, Blohmner JU, Dan Costa S, Gerber B, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol 2006; 13:1434-42.
4. Kauf H, Haisin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999;230:72-8.
5. Kauf H, Newman LA, Fornage BD, Dhirgra K, Hunt KK, Buzdar AU, et al. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol 1998;5:673-80.
6. Vlastos G, Mirza NQ, Lenert JT, Hunt KK, Ames FC, Feig BW, et al. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer 2000;88:1417-24.
7. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703-20.
8. von Minckwitz G, Kimm ML, Vogel P, Hanusch C, Eitlmann H, Hilfrich J, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100:552-62.
9. von Minckwitz G, Blohmner JU, Raab G, Lühr A, Gerber B, Heinrich G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005;16:56-63.
10. von Minckwitz G, Untch M, Blohmner JU, Costa SD, Eitlmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-804.
11. Yao C, Ahn JH, Jung KH, Kim SB, Kim HH, Shin HJ, et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity
and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer 2012;15:203-10.

12. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.

13. Bhargava R, Bertiwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer 2010;116:1431-9.

14. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.

15. Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am 2003;83:931-42.

16. Rouzier R, Extra JM, Klijianienko J, Falcou MC, Asselain B, Vincent-Salomon A, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002;20:1304-10.

17. Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breast cancer. Br J Surg 2005;92:14-23.

18. Nason KS, Anderson BO, Byrd DR, Dunnwald IJ, Eary JF, Mankoff DA, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000; 89:2187-94.

19. Pecha V, Kolarik D, Kozevnikova R, Hovorkova K, Hrabecova P, Halaska M, et al. Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Cancer 2011;117:4606-16.

20. Gimbargues P, Abridal C, Durando X, Le Bouedec G, Cachin F, Penault-Llorca F, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol 2008;15:1316-21.

21. Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowl Project Protocol B-27. J Clin Oncol 2005;23:2694-702.

22. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006;93:339-46.

23. Boughen JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013;310:1455-61.

24. Straver ME, Rutgers EJ, Russell NS, Oldenburg HS, Rodenhuis S, Wesseling J, et al. Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer. Eur J Cancer 2009;45:2284-92.

25. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567-75.

26. Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009;27:2946-53.